SLC5A2 and type 2 diabetes mellitus: At the end of the analysis, it was concluded that SGLT-2 inhibitor use was associated with an overall lower risk of hospitalizations for heart failure and death, suggesting that the benefits seen with empagliflozin may apply to a general population of patients with T2DM in the real-world [10].